Stock GSK GSK PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials GSK plc Nyse

Equities

GSK

US37733W2044

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 01:30:03 29/06/2024 am IST 		5-day change 1st Jan Change
38.5 USD -0.36% Intraday chart for GSK plc -4.89% +3.89%
28/06 GSK reaches settlement over Zantac case in Illinois AN
28/06 GSK Reaches Settlement in Illinois Zantac Lawsuit DJ

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 88,051 66,801 80,458 58,381 59,112 62,374 - -
Enterprise Value (EV) 1 1,13,773 87,581 1,00,296 75,578 74,152 74,501 71,060 67,061
P/E ratio 19.2 x 11.8 x 18.6 x 3.93 x 11.9 x 11.5 x 9.67 x 8.76 x
Yield 4.5% 5.96% 4.98% 4.26% 4% 3.97% 4.12% 4.31%
Capitalization / Revenue 2.61 x 1.96 x 2.36 x 1.99 x 1.95 x 1.97 x 1.85 x 1.75 x
EV / Revenue 3.37 x 2.57 x 2.94 x 2.58 x 2.45 x 2.35 x 2.11 x 1.88 x
EV / EBITDA 9.51 x 9.19 x 8.85 x 7.23 x 6.37 x 7.01 x 6.07 x 5.28 x
EV / FCF 22.4 x 16.2 x 22.6 x 12.1 x 13.6 x 12.7 x 9.93 x 8.83 x
FCF Yield 4.46% 6.17% 4.42% 8.28% 7.36% 7.9% 10.1% 11.3%
Price to Book 7.35 x 4.58 x 5.34 x 5.47 x 4.4 x 3.89 x 3.19 x 2.64 x
Nbr of stocks (in thousands) 39,59,572 39,82,185 40,06,383 40,60,999 40,76,145 40,78,064 - -
Reference price 2 22.24 16.78 20.08 14.38 14.50 15.30 15.30 15.30
Announcement Date 05/02/20 03/02/21 09/02/22 01/02/23 31/01/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,754 34,099 34,114 29,324 30,328 31,652 33,639 35,591
EBITDA 1 11,968 9,530 11,330 10,449 11,635 10,624 11,708 12,698
EBIT 1 8,972 8,906 8,806 8,151 8,786 9,196 10,199 11,253
Operating Margin 26.58% 26.12% 25.81% 27.8% 28.97% 29.05% 30.32% 31.62%
Earnings before Tax (EBT) 1 6,221 6,968 5,442 5,628 6,064 7,474 8,814 9,827
Net income 1 4,645 5,749 4,385 14,956 4,928 5,498 6,492 7,155
Net margin 13.76% 16.86% 12.85% 51% 16.25% 17.37% 19.3% 20.1%
EPS 2 1.158 1.426 1.082 3.662 1.216 1.335 1.581 1.746
Free Cash Flow 1 5,073 5,406 4,437 6,260 5,454 5,889 7,158 7,594
FCF margin 15.03% 15.85% 13.01% 21.35% 17.98% 18.61% 21.28% 21.34%
FCF Conversion (EBITDA) 42.39% 56.73% 39.16% 59.91% 46.88% 55.43% 61.14% 59.8%
FCF Conversion (Net income) 109.21% 94.03% 101.19% 41.86% 110.67% 107.12% 110.27% 106.13%
Dividend per Share 2 1.000 1.000 1.000 0.6125 0.5800 0.6069 0.6302 0.6600
Announcement Date 05/02/20 03/02/21 09/02/22 01/02/23 31/01/24 - - -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 9,527 9,780 6,929 7,829 7,376 6,951 7,178 8,147 8,052 7,363 7,533 8,534 8,219 7,590 7,865
EBITDA 1 2,406 3,317 2,639 3,561 1,602 2,732 2,622 3,351 2,930 2,992 2,594 3,095 1,835 - -
EBIT 1 1,893 2,613 2,008 2,605 1,595 2,092 2,170 2,772 1,752 2,443 2,216 2,793 1,757 2,408 2,487
Operating Margin 19.87% 26.72% 28.98% 33.27% 21.62% 30.1% 30.23% 34.02% 21.76% 33.18% 29.42% 32.72% 21.37% 31.73% 31.62%
Earnings before Tax (EBT) 1 706 2,598 896 1,012 1,626 1,907 1,987 1,791 379 1,355 1,823 2,493 1,317 - -
Net income 1 749 1,802 975 10,315 1,495 1,490 1,624 1,464 350 1,046 1,425 1,877 1,214 - -
Net margin 7.86% 18.43% 14.07% 131.75% 20.27% 21.44% 22.62% 17.97% 4.35% 14.21% 18.92% 21.99% 14.77% - -
EPS 2 0.1838 0.4488 0.2080 2.523 0.3650 0.3650 0.4010 0.3610 0.0860 0.2540 0.3505 0.4565 0.2280 - -
Dividend per Share 2 0.2875 0.1750 0.1625 0.1375 0.1375 0.1400 0.1400 0.1400 0.1600 0.1500 0.1500 0.1500 0.1500 0.1594 0.1594
Announcement Date 09/02/22 27/04/22 27/07/22 02/11/22 01/02/23 26/04/23 26/07/23 01/11/23 31/01/24 01/05/24 - - - - -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 25,722 20,780 19,838 17,197 15,040 12,127 8,686 4,687
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.149 x 2.18 x 1.751 x 1.646 x 1.293 x 1.141 x 0.7418 x 0.3691 x
Free Cash Flow 1 5,073 5,406 4,437 6,260 5,454 5,889 7,158 7,594
ROE (net income / shareholders' equity) 75% 44.4% 38.2% 43.9% 52.5% 42% 38.3% 34.8%
ROA (Net income/ Total Assets) 8.9% 7.18% 5.5% 8.08% 10.5% 9.68% 10.7% 11.2%
Assets 1 52,185 80,062 79,768 1,85,120 46,727 56,803 60,696 63,849
Book Value Per Share 2 3.020 3.660 3.760 2.630 3.290 3.930 4.800 5.790
Cash Flow per Share 2 2.000 2.090 1.960 1.810 1.670 1.860 1.850 1.980
Capex 1 1,265 1,226 1,172 1,143 1,314 1,774 1,659 1,653
Capex / Sales 3.75% 3.6% 3.44% 3.9% 4.33% 5.6% 4.93% 4.64%
Announcement Date 05/02/20 03/02/21 09/02/22 01/02/23 31/01/24 - - -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.3 GBP
Average target price
20.28 GBP
Spread / Average Target
+32.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 82TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 64TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 31TCr
ABBVIE INC. Stock AbbVie Inc.
+10.68% 30TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 24TCr
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 22TCr
NOVARTIS AG Stock Novartis AG
+13.31% 22TCr
AMGEN INC. Stock Amgen Inc.
+8.48% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. GSK Stock
  5. Financials GSK plc